
Discovery
Generate high‑performing GS® cell lines early and set a strong, predictable foundation for everything that follows.

Early development
Select and optimize lead candidates to prepare for IND‑enabling work with fewer surprises and clearer CMC plans.

DNA to IND
Advance to IND with integrated CMC development and GMP manufacturing, benefiting from proven timelines, quality and IND‑ready documentation.

Commercial production
Scale seamlessly to commercial supply, maintaining continuity, performance and long‑term confidence.
Move faster with confidence, from discovery to commercial production, on a proven, regulator‑familiar expression platform with no license fees when you manufacture with Lonza.
100+
Commercial biotherapeutics manufactured using GS®.
30
Years of expertise in bioproduction. Continuously innovating.
100%
Success rate in delivery of
IND-enabling CMC modules.
Trusted
Proven performance. Familiar
to regulators.

*T& apply
If the Product is manufactured at a Lonza facility, then in accordance with the GS® license in respect of that Product, no milestone payments fees and no royaltyies on net sales will be due in respect of that Product, provided that the Product remains solely manufactured by Lonza.
If the Product is not manufactured at a Lonza facility, then in accordance with the GS® license in respect of that Product, fees and royalties shall be payable.
Why choose Lonza?
Comprehensive pre-clinical services
End-to-end solutions from early development to GMP manufacturing, powered by our proven GS Gene Expression System®.
Flexible development options
Accelerate your path to clinic with an integrated DNA to IND program or customize it to your specific milestones, meeting your unique project and molecule needs.
Unmatched expertise
With a 100% success rate for IND-enabling CMC modules, leverage our technical and regulatory expertise to navigate complex development and submission processes confidently at every stage.
What could you do with the fees you won't pay? Submit the form and our experts will be in touch.